ASH 2020 | Ponatinib, venetoclax and dexamethasone in R/R Ph+ ALL
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares interim results from a Phase I/II trial (NCT03576547) of ponatinib, venetoclax and dexamethasone combination therapy in relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is a pan-BCR-ABL tyrosine kinase inhibitor that shows strong but short-lived activity in Ph+ ALL. Given its dependency on BCL-2, the addition of another BCl-2 inhibitor, venetoclax, may improve treatment outcomes for Ph+ ALL. To date, enrolled patients have received either 400mg or 800mg of venetoclax daily. The maximum tolerated dose has not yet been reached and no dose-limiting toxicities have occurred. 50% of patients achieved complete remission, all of whom were receiving the 800mg venetoclax dose. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
